Why We Don’t Prescribe Compounded GLP-1s

Our Position

For weight management, PEAK Wellness & Aesthetics prescribes FDA-approved brand-name medications including Wegovy and Zepbound. We do not prescribe compounded semaglutide or compounded tirzepatide under any circumstance.

This is a deliberate clinical and ethical decision rooted in patient safety, legal compliance, and quality assurance—not pricing strategy.

We know compounded versions are widely available. We know they’re marketed as “the same thing, just cheaper.” And we know many patients have used them without obvious problems. But the documented risks are real, and we don’t believe it’s responsible to prescribe products we can’t verify.

What “Compounded” Actually Means

Compounding is when a pharmacy creates a customized medication by mixing ingredients according to a prescription. It’s legitimate in narrow situations—when a patient needs a dose that isn’t commercially available, or has an allergy to an inactive ingredient in the standard formulation.

But compounded drugs are not FDA-approved. They don’t go through the same rigorous testing for safety, effectiveness, and quality that brand-name medications do. The FDA doesn’t review them before they reach patients.^[1]

During the 2022–2025 shortage period for Wegovy, Zepbound, and related medications, the FDA temporarily allowed compounding pharmacies to produce semaglutide and tirzepatide under “enforcement discretion.” That period has ended.^[6]

The FDA’s Documented Concerns

The FDA has issued multiple warnings about compounded GLP-1 products. These aren’t theoretical—they’re based on actual adverse event reports.

Dosing Errors Leading to Hospitalizations

Compounded semaglutide and tirzepatide typically come in multi-dose vials requiring patients to measure and draw up their own injections. Confusion between milligrams (mg), milliliters (mL), and “units” has caused patients to accidentally inject 5 to 20 times the intended dose.^[3]

Wegovy and Zepbound come in pre-filled pens with fixed doses.^[4][5] No measuring, no math, no room for a 10x overdose.

FDA Safety Alert: The FDA has received reports of adverse events, some requiring hospitalization, linked to compounded semaglutide products. In reported dosing-error cases, patients injected 5 to 20 times the intended dose.^[3]

Different Chemical Forms That Haven’t Been Tested

Some compounding pharmacies use salt forms of semaglutide—such as semaglutide sodium or semaglutide acetate—instead of the base form used in Wegovy and Ozempic.^[1]

The FDA has stated clearly: these salt forms are different active ingredients than what’s in the approved drugs. There’s no evidence they work the same way. There’s no evidence they’re safe. And there’s no legal basis for using them in compounding.^[2]

Quality and Sterility Concerns

In 2024–2025, the FDA issued warning letters and public alerts involving compounded GLP-1 products and ingredients. Documented problems include sterility failures, products from unregistered facilities, labels that don’t match the actual source, bulk ingredients from unverified suppliers, and product-quality concerns.^[1][2]

Because adverse event reporting isn’t required for most state-licensed pharmacies, the actual number of problems is likely far higher than what’s been documented.

“But It’s the Same Active Ingredient”

This is the most common argument for compounded products. It sounds logical but falls apart under scrutiny.

FDA-approved drugs aren’t just about the active ingredient. They’re about purity (is the raw ingredient pharmaceutical-grade?), formulation (is it mixed correctly and consistently?), stability (does it remain effective over time?), dosing accuracy (does each dose contain exactly what it should?), and delivery mechanism (is it administered in a way that reduces error?).

Novo Nordisk (Wegovy) and Eli Lilly (Zepbound) have invested billions of dollars to ensure consistency across every pen they produce. Compounding pharmacies—even legitimate ones—don’t have the same level of quality control.

And some of what’s sold as “compounded semaglutide” isn’t even the same chemical.

The Legal Landscape (2025–Present)

During the shortage, compounding was a gray area. It is now much more clear-cut.^[6]

Compounding semaglutide or tirzepatide is now only permitted under very limited circumstances—for example, when a patient has a documented allergy to an inactive ingredient in the approved product.

“I want it cheaper” is not a valid compounding indication.

Many telehealth companies that built their business on compounded GLP-1s are now in a difficult spot. Some have pivoted. Others continue operating and hope they won’t be enforced against. PEAK does not want to put patients in that position.

Wegovy vs. Compounded Semaglutide

Zepbound vs. Compounded Tirzepatide

Cost: The Real Comparison

The price gap can be real, but it depends heavily on dose, insurance, and manufacturer programs.

How PEAK Helps With Cost

We work with insurance. Many commercial plans cover Wegovy and Zepbound with prior authorization. We handle the PA process and fight denials on your behalf.

We prescribe both medications. If your insurance covers Zepbound but not Wegovy (or vice versa), we work with what’s available. Having both options means more coverage possibilities.

We’re transparent about self-pay options. Novo Nordisk and Eli Lilly both offer direct pricing programs that can narrow the gap for many patients—with FDA-approved safety standards.^[7][8] And with no generic version of Wegovy yet available, these manufacturer programs are often the best cash-pay path.

We focus on sustainability. A medication that costs less but doesn’t work—or lands you in the ER—isn’t actually saving money.

Already on a Compounded Medication?

If you’re currently using compounded semaglutide or tirzepatide and want to transition to an FDA-approved version, we can help. This is a growing part of our practice since enforcement discretion ended.

Common reasons patients switch: their compounding pharmacy stopped filling prescriptions, their telehealth provider pivoted or shut down, they have concerns about quality or dosing accuracy, their insurance now covers the FDA-approved version, or they simply want the convenience and safety of pre-filled pens. Read our guide on switching from a compounded GLP-1 to FDA-approved medication.

How the Transition Works

Consultation and dose assessment. We review your current compounded dose, how long you’ve been on it, and your response. Because compounded products vary in concentration, potency, and even chemical form, we can’t assume equivalence.

Timing. Standard approach: wait 7 days after your last compounded injection before starting the FDA-approved medication. If the gap exceeds two weeks, we may treat it more like a new start.

Insurance and prior authorization. We check your benefits and submit a prior authorization within 48 hours. If it’s denied, we handle appeals.

Ongoing monitoring. Monthly visits during dose titration, then every 1–3 months at your maintenance dose.

Most patients at equivalent doses don’t notice a significant difference. Some report more consistent appetite suppression thanks to standardized dosing. If timed correctly, there’s typically no meaningful return of appetite during the transition.

The PEAK Clinical Team

PEAK Wellness & Aesthetics

Evidence-based guidance from our board-certified clinicians specializing in medical weight loss and obesity medicine.